Bluebird Bio Says Continuing To Work Expeditiously To Complete Delayed Filings
Bluebird Bio Says Continuing To Work Expeditiously To Complete Delayed Filings
Bluebird Bio表示将继续尽快完成延迟的申报
On March 26, 2024, bluebird announced that it will restate its consolidated financial statements for the first three quarters and full-year 2022, as well as the first three quarters of 2023. As a result, the Company's Annual Report Form 10-K for 2023 and its Q1 2024 Form 10-Q have been delayed.
2024年3月26日，蓝鸟宣布将重报2022年前三个季度和全年以及2023年前三个季度的合并财务报表。因此，公司2023年10-K年度报告表和2024年第一季度10-Q表被推迟。
Consistent with previous updates, the restatement is not expected to impact the Company's cash position or revenue. Sterling will transition to oversee the restatement process upon his start date.
与之前的更新一致，重报预计不会影响公司的现金状况或收入。斯特林将在开始时过渡到监督重报流程。
资讯热榜
更新时间